Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
Open Access
- 4 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1584675
Abstract
The expanding clinical utilization of immune checkpoint inhibitors (ICIs) in oncology has brought increasing attention to thyroid dysfunction as a prominent immune-related adverse event (irAE). Elucidating the pathophysiological mechanisms underlying ICI-induced thyroiditis represents a critical step toward developing evidence-based diagnostic protocols and targeted therapeutic interventions for cancer patients undergoing immunotherapy. This comprehensive review systematically examines current advances in understanding the etiopathogenesis of ICI-induced thyroiditis. First, we described pharmacological characterization of ICIs, then discussed multifactorial analysis of cellular and molecular contributors to thyroid autoimmunity following ICI administration and finally analyzed critical evaluation of emerging hypotheses regarding primary pathogenic drivers. Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology.Keywords
This publication has 117 references indexed in Scilit:
- Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitorsBasic Research in Cardiology, 2024
- The genetics of Graves’ diseaseReviews in Endocrine and Metabolic Disorders, 2023
- Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant MelanomaJAMA Network Open, 2022
- Role of the PD‐1/PD‐L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future DirectionsMolecular Neurobiology, 2021
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical PearlsCurrent Oncology Reports, 2020
- Functions of Immune Checkpoint Molecules Beyond Immune Evasion2020
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung CancerJAMA Oncology, 2019
- The pathogenesis of thyroid autoimmune diseases: New T lymphocytes – Cytokines circuits beyond the Th1−Th2 paradigmJournal of Cellular Physiology, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Molecular mimicry and autoimmune thyroid diseaseReviews in Endocrine and Metabolic Disorders, 2016